Sanofi-Aventis takes control of Genzyme
This article was originally published in Scrip
Sanofi-Aventis finally has control of Genzyme. Having completed its exchange offer, it now holds 84.6% of Genzyme's outstanding shares of common stock, or 77% of the shares on a fully diluted basis.
You may also be interested in...
This year Sanofi will "begin to make our success sustainable," said CEO Olivier Brandicourt in a 2017 financial earnings broadcast; despite a weak finish to 2017 and lower than expected guidance for this year, Sanofi's chief exec is upbeat.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.